Clazakizumab

Unassigned

New Medicines

Renal transplant chronic active antibody-mediated rejection

Information

New molecular entity
Vitaeris
Vitaeris

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Interleukin-6 (IL6) inhibitor produced using yeast cells
Most kidney transplants develop chronic rejection within a decade, and there are currently no effective treatment options [2].
Renal transplant chronic active antibody-mediated rejection
Subcutaneous